FWIW, Small mention of BTGC in this link. Looks like Paul picked BTGC as his mid-cap biotech play.
Let others bet on genomics stocks
Tuesday, Jun. 27, 2000 07:23 PDT
By Paul Schneider, America-iNvest.com
I don't want to spoil the party, what with the big deal being made of Celera Genomics (CRA) and the government-funded Human Genome Project showing off their rough draft of the genetic code for human life.
OK, I do want to spoil the party, and for good reason. Nobody should be buying genomics stocks such as Celera, or stocks of any other stripe, because of public fanfare. Snip\/.
americainvest.com
Here is the original post of his pick in Dec. '99:
A mid-cap on the grow: BTGC
If something middle-sized is more to your liking, you might try rising star Bio-Technology General (BTGC), with a $638 million market cap (compared to Merck's staggering $156 billion market cap). Headquartered in Iselin, N.J., Bio-Technology General makes products for conditions such as endocrine/metabolic and ophthalmic/skin disorders and cardio/pulmonary diseases.
Bio-Technology General's marketing arrangement with Teva Pharmaceutical Industries Ltd. (TEVA) should help the company grow. Bio-Technology General's role in the deal is to develop and manufacture products for which Teva has exclusive marketing rights. Teva is Israel's largest pharmaceutical company, with 80% of its sales outside Israel, mainly in the United States.
Bio-Technology General closed Dec. 20 at $12.06.
Jim |
